RU2003119460A - Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с - Google Patents
Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита сInfo
- Publication number
- RU2003119460A RU2003119460A RU2003119460/14A RU2003119460A RU2003119460A RU 2003119460 A RU2003119460 A RU 2003119460A RU 2003119460/14 A RU2003119460/14 A RU 2003119460/14A RU 2003119460 A RU2003119460 A RU 2003119460A RU 2003119460 A RU2003119460 A RU 2003119460A
- Authority
- RU
- Russia
- Prior art keywords
- peg
- ifn
- ribavirin
- conjugate
- chronic hepatitis
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims 6
- 229960000329 Ribavirin Drugs 0.000 title claims 6
- 208000006154 Chronic Hepatitis C Diseases 0.000 title claims 5
- 208000005176 Hepatitis C Diseases 0.000 title claims 5
- 201000010099 disease Diseases 0.000 claims 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
Claims (9)
1. Применение конъюгатов ПЭГ-IFN-α в сочетании с рибавирином для приготовления лекарственного средства, предназначенного для лечения заболеваний хроническим гепатитом С.
2. Применение по п.1, где количество конъюгата ПЭГ-IFN-α составляет приблизительно от 33 до 540 мкг/неделю.
3. Применение по п.1, где количество рибавирина составляет от 400 до 1200 мг/день.
4. Применение по п.п.1-3, где конъюгат ПЭГ-IFN-α представляет собой конъюгат ПЭГ-IFN-α2А формулы
где R и R’ обозначают метил, Х обозначает NH и n и n’ каждый по отдельности или оба равны 420 или 520.
5. Способ лечения заболевания хроническим гепатитом С, предусматривающий введение конъюгата ПЭГ-IFN-α в сочетании с рибавирином в количествах, эффективных для лечения хронического гепатита С.
6. Способ по п.5, где количество конъюгата ПЭГ-IFN-α, вводимого согласно указанному способу, составляет приблизительно 33-540 мкг/неделю.
7. Способ по п.5, где количество рибавирина, вводимого согласно указанному способу, составляет 400-1200 мг/день.
8. Способ по любому из п.п.5-7, где вводимый конъюгат ПЭГ-IFN-α представляет собой ПЭГ-IFN-α2А.
9. Применение конъюгата ПЭГ-IFN-α и рибавирина для лечения заболеваний хроническим гепатитом С.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98110433.4 | 1998-06-08 | ||
| EP98110433 | 1998-06-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001101445/14A Division RU2001101445A (ru) | 1998-06-08 | 1999-05-29 | Применение пэг-интерферона-альфа (пэг-ifn-альфа) и рибавирина для лечения хронического гепатита с |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003119460A true RU2003119460A (ru) | 2004-12-20 |
| RU2271217C2 RU2271217C2 (ru) | 2006-03-10 |
Family
ID=8232086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003119460/14A RU2271217C2 (ru) | 1998-06-08 | 1999-05-29 | ПРИМЕНЕНИЕ ПЭГ-ИНТЕРФЕРОНА-α(ПЭГ-IFN-α) И РИБАВИРИНА ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20030053986A1 (ru) |
| EP (1) | EP1087778B1 (ru) |
| JP (2) | JP3839667B2 (ru) |
| KR (2) | KR20010052622A (ru) |
| CN (1) | CN1170543C (ru) |
| AR (1) | AR019855A1 (ru) |
| AT (1) | ATE307597T1 (ru) |
| AU (1) | AU767131B2 (ru) |
| BR (1) | BR9911076A (ru) |
| CA (1) | CA2334267C (ru) |
| CL (1) | CL2010000828A1 (ru) |
| CO (1) | CO5050297A1 (ru) |
| CZ (1) | CZ298681B6 (ru) |
| DE (1) | DE69927971T2 (ru) |
| DK (1) | DK1087778T3 (ru) |
| ES (1) | ES2251196T3 (ru) |
| HK (1) | HK1037981A1 (ru) |
| HR (1) | HRP20000808A2 (ru) |
| HU (1) | HU228218B1 (ru) |
| ID (1) | ID29285A (ru) |
| IL (2) | IL139786A0 (ru) |
| MA (1) | MA26641A1 (ru) |
| MY (1) | MY124091A (ru) |
| NO (1) | NO325598B1 (ru) |
| NZ (1) | NZ508249A (ru) |
| PE (1) | PE20000560A1 (ru) |
| PL (1) | PL192364B1 (ru) |
| RS (1) | RS50144B (ru) |
| RU (1) | RU2271217C2 (ru) |
| SA (1) | SA99200208B1 (ru) |
| SI (1) | SI1087778T1 (ru) |
| TR (1) | TR200003635T2 (ru) |
| TW (1) | TWI241913B (ru) |
| WO (1) | WO1999064016A1 (ru) |
| ZA (1) | ZA200006814B (ru) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1087778T1 (sl) * | 1998-06-08 | 2006-02-28 | Hoffmann La Roche | Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| CA2418085A1 (en) * | 2000-08-07 | 2002-02-14 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| KR100480429B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체 |
| NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| EP1536804A4 (en) | 2002-06-28 | 2007-10-31 | Idenix Cayman Ltd | 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS |
| EP2799442A1 (en) | 2002-06-28 | 2014-11-05 | IDENIX Pharmaceuticals, Inc. | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
| HUE033832T2 (en) * | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
| MXPA05006230A (es) * | 2002-12-12 | 2005-09-20 | Idenix Cayman Ltd | Proceso para la produccion de nucleosidos ramificados-2'. |
| RU2005123395A (ru) * | 2002-12-23 | 2006-01-27 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 3-нуклеозидных пролекарств |
| ES2586668T3 (es) | 2003-05-30 | 2016-10-18 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
| US20060040944A1 (en) * | 2004-06-23 | 2006-02-23 | Gilles Gosselin | 5-Aza-7-deazapurine derivatives for treating Flaviviridae |
| US7640048B2 (en) | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
| MX2007003085A (es) | 2004-09-14 | 2007-08-02 | Pharmasset Inc | Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados. |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006281498A1 (en) * | 2005-08-15 | 2007-02-22 | F. Hoffmann-La Roche Ag | PEG-IFN alpha and ribavirin for HBV treatment |
| US9201979B2 (en) * | 2005-09-14 | 2015-12-01 | Millennial Media, Inc. | Syndication of a behavioral profile associated with an availability condition using a monetization platform |
| WO2007075876A2 (en) * | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| AU2009264214B2 (en) | 2008-06-24 | 2013-06-06 | Technische Universitaet Muenchen | Muteins of hNGAL and related proteins with affinity for a given target |
| WO2010033443A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
| NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
| US8716012B2 (en) | 2009-05-08 | 2014-05-06 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| IN2012DN00407A (ru) | 2009-08-05 | 2015-08-21 | Pieris Ag | |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| US9549968B2 (en) | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
| AU2011235112B2 (en) | 2010-03-31 | 2015-07-09 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TR201906295T4 (tr) | 2010-06-08 | 2019-05-21 | Astrazeneca Ab | IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri. |
| AU2011290751B2 (en) | 2010-08-16 | 2015-08-13 | Pieris Ag | Binding proteins for Hepcidin |
| AU2011331232B2 (en) | 2010-11-15 | 2015-05-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
| DK2646552T3 (en) | 2010-12-02 | 2017-10-23 | Pieris Pharmaceuticals Gmbh | MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4 |
| NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| AU2012350660B2 (en) | 2011-12-13 | 2018-01-25 | Astrazeneca Ab | Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US20140039923A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for receiving and managing patient data gathered during patient treatments |
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| LT2950786T (lt) | 2013-01-31 | 2020-03-10 | Gilead Pharmasset Llc | Dviejų antivirusinių junginių preparatų kompozicija |
| SG11201505856TA (en) | 2013-03-14 | 2015-08-28 | Daiichi Sankyo Co Ltd | Novel binding proteins for pcsk9 |
| NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| EP3789397B1 (en) | 2014-05-22 | 2023-12-06 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP3250586B1 (en) | 2015-01-28 | 2021-10-27 | Pieris Pharmaceuticals GmbH | Novel proteins specific for angiogenesis |
| JP6843754B2 (ja) | 2015-02-18 | 2021-03-17 | ピエリス ファーマシューティカルズ ゲーエムベーハー | ピオベルジン及びピオケリンに特異的な新規なタンパク質 |
| CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| WO2016177762A1 (en) | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| ES2938525T3 (es) | 2015-05-18 | 2023-04-12 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anticanceroso |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| US10501510B2 (en) | 2015-07-15 | 2019-12-10 | Pieris Pharmaceuticals Gmbh | Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof |
| US10703810B2 (en) | 2015-11-30 | 2020-07-07 | Pieris Australia Pty Ltd. | Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| EP3571219A1 (en) | 2017-01-18 | 2019-11-27 | Pieris Pharmaceuticals GmbH | Lipocalin muteins with binding affinity for lag-3 |
| KR20210040103A (ko) | 2018-07-31 | 2021-04-12 | 피어이스 파마슈티컬즈 게엠베하 | Cd137 및 pd-l1에 특이적인 신규한 융합 단백질 |
| SG11202106353VA (en) | 2019-02-26 | 2021-07-29 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| CA3177098A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
| WO2022214649A1 (en) | 2021-04-08 | 2022-10-13 | Pieris Pharmaceuticals Gmbh | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) |
| WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
| WO2024064713A1 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681848A (en) * | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3719046A1 (de) * | 1987-06-06 | 1988-12-15 | Basf Ag | Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5238915A (en) * | 1991-02-08 | 1993-08-24 | Wakunaga Seiyaku K.K. | Aromatic composition and method for controlling aroma |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| ES2174915T3 (es) * | 1993-11-10 | 2002-11-16 | Enzon Inc | Productos de conjugacion mejorados de un interferon con un polimero. |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| US5695760A (en) * | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| CA2329474C (en) * | 1995-11-02 | 2002-02-26 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| SI1087778T1 (sl) * | 1998-06-08 | 2006-02-28 | Hoffmann La Roche | Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c |
-
1999
- 1999-05-29 SI SI9930843T patent/SI1087778T1/sl unknown
- 1999-05-29 BR BR9911076-8A patent/BR9911076A/pt not_active Application Discontinuation
- 1999-05-29 RU RU2003119460/14A patent/RU2271217C2/ru active
- 1999-05-29 CZ CZ20004487A patent/CZ298681B6/cs not_active IP Right Cessation
- 1999-05-29 JP JP2000553084A patent/JP3839667B2/ja not_active Expired - Lifetime
- 1999-05-29 CA CA002334267A patent/CA2334267C/en not_active Expired - Lifetime
- 1999-05-29 IL IL13978699A patent/IL139786A0/xx active IP Right Grant
- 1999-05-29 AU AU45033/99A patent/AU767131B2/en not_active Expired
- 1999-05-29 KR KR1020007013843A patent/KR20010052622A/ko active Search and Examination
- 1999-05-29 ES ES99927804T patent/ES2251196T3/es not_active Expired - Lifetime
- 1999-05-29 AT AT99927804T patent/ATE307597T1/de active
- 1999-05-29 PL PL344794A patent/PL192364B1/pl unknown
- 1999-05-29 KR KR1020057009098A patent/KR20050055053A/ko not_active Application Discontinuation
- 1999-05-29 RS YUP-770/00A patent/RS50144B/sr unknown
- 1999-05-29 EP EP99927804A patent/EP1087778B1/en not_active Expired - Lifetime
- 1999-05-29 DK DK99927804T patent/DK1087778T3/da active
- 1999-05-29 TR TR2000/03635T patent/TR200003635T2/xx unknown
- 1999-05-29 WO PCT/EP1999/003746 patent/WO1999064016A1/en active IP Right Grant
- 1999-05-29 NZ NZ508249A patent/NZ508249A/xx not_active IP Right Cessation
- 1999-05-29 ID IDW20002551A patent/ID29285A/id unknown
- 1999-05-29 HU HU0102033A patent/HU228218B1/hu unknown
- 1999-05-29 CN CNB998071706A patent/CN1170543C/zh not_active Expired - Lifetime
- 1999-05-29 DE DE69927971T patent/DE69927971T2/de not_active Expired - Lifetime
- 1999-06-02 SA SA99200208A patent/SA99200208B1/ar unknown
- 1999-06-04 PE PE1999000478A patent/PE20000560A1/es not_active Application Discontinuation
- 1999-06-04 TW TW088109246A patent/TWI241913B/zh not_active IP Right Cessation
- 1999-06-04 AR ARP990102664A patent/AR019855A1/es not_active Application Discontinuation
- 1999-06-04 CO CO99035303A patent/CO5050297A1/es unknown
- 1999-06-07 MY MYPI99002297A patent/MY124091A/en unknown
- 1999-06-08 MA MA25613A patent/MA26641A1/fr unknown
-
2000
- 2000-11-20 IL IL139786A patent/IL139786A/en not_active IP Right Cessation
- 2000-11-21 ZA ZA200006814A patent/ZA200006814B/en unknown
- 2000-11-24 HR HR20000808A patent/HRP20000808A2/hr not_active Application Discontinuation
- 2000-12-05 NO NO20006178A patent/NO325598B1/no not_active IP Right Cessation
-
2001
- 2001-11-07 US US10/037,064 patent/US20030053986A1/en not_active Abandoned
- 2001-12-20 HK HK01108946A patent/HK1037981A1/xx not_active IP Right Cessation
-
2004
- 2004-07-26 US US10/899,726 patent/US20050031589A1/en not_active Abandoned
-
2006
- 2006-02-02 JP JP2006025756A patent/JP2006160759A/ja active Pending
-
2007
- 2007-01-24 US US11/657,287 patent/US20070196385A1/en not_active Abandoned
-
2010
- 2010-08-04 CL CL2010000828A patent/CL2010000828A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003119460A (ru) | Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| HUP0300421A2 (hu) | Kezelési eljárás ligand-immunogén konjugátumok felhasználásával | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| DE69232263T2 (de) | Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen | |
| RU2004110055A (ru) | Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов | |
| KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
| ATE170077T1 (de) | Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| EP1431286A3 (en) | Prodigiosin derivatives for treating cancer or viral diseases | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| KR950016760A (ko) | 치질 치료제 | |
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| JP2003514025A5 (ru) | ||
| KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
| RU2001101445A (ru) | Применение пэг-интерферона-альфа (пэг-ifn-альфа) и рибавирина для лечения хронического гепатита с | |
| EA200400348A1 (ru) | Цисплатиновые составы пониженной токсичности и способы их применения | |
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| CA2343120A1 (en) | Use of an anthracycline derivative for the treatment of a liver tumor | |
| RU2004116067A (ru) | Фармацевтические композиции, содержащие макролиды | |
| RU99118510A (ru) | Композиция для лечения или предупреждения рака простаты | |
| JPH0251405B2 (ru) | ||
| KR950031082A (ko) | 우르소데옥시콜린산의 신규한 유도체와 이를 포함하는 제약학적 성분물 | |
| RU2002100065A (ru) | Применение верапамила и производных верапамила для получения лекарственных средств с действием, ингибирующим β-глюкуронидазу в ткани человека | |
| RU97110383A (ru) | Способ профилактики и лечения атеросклероза |